Discover comprehensive details about Trabectedin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

US-based biotechnology company Sonnet BioTherapeutics has expanded its Phase I SB101 study of SON-1010 for advanced solid tumours. The company is adding a cohort to assess the efficacy of SON-1010 ...

Combining trabectedin and olaparib showed marginal improvement in progression-free survival for advanced soft tissue sarcomas, with notable benefits in specific subgroups. Patients with PARP1 ...

Patients with recurrent ovarian cancer who carry the BRCA1 mutation may experience improved survival when treated with a chemotherapeutic combination containing the orphan drug trabectedin.

Soft tissue sarcomas (STS) are a complex, heterogeneous group of more than 50 neoplasms of mesenchymal origin. According to the American Cancer Society, in 2015, approximately 11,930 patients in the ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of trabectedin, having considered evidence on the nature of advanced soft tissue sarcoma and the value placed ...

HORSHAM, Pa., Sept. 10 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the ...

• Trabectedin injection should be given directly into the vein through a separate central venous line very slowly for 24 hours. • Trabectedin powder for reconstitution should be mixed with 20 ml of ...

Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of ...

A multicenter, open-label, uncontrolled phase II study of ONO-4538 for cutaneous angiosarcoma (Angio Check study). This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract ...

July 7, 2010 — Trabectedin (Yondelis) has been approved in Europe, Canada, and other regions of the world for use in platinum-sensitive recurrent ovarian cancer, but it is not available in the United ...